StimCardio Medical Closes $30 Million Oversubscribed Series A To Advance Atrial Fibrillation Treatment

Los Angeles-based StimCardio Medical, founded by Amos Ziv and Tsahi Holand, has closed an oversubscribed $30 million Series A round led by Metis MedTech, with participation from Catalyst Health Ventures, multiple corporate strategic investors, and other new and existing investors. The company is developing Rhyvive, an investigational wrist-worn device that uses non-invasive median nerve stimulation to treat atrial fibrillation, with the funding supporting further clinical development and its planned NeuroPulse 2 pivotal study.

FUN FACT: What if the next major advancement in atrial fibrillation (AF) treatment could be worn on your wrist? Approximately 59 million people worldwide live with AF, and 30% to 40% of patients experience recurrence following catheter ablation, highlighting a significant unmet clinical need. StimCardio is developing Rhyvive, an investigational wrist-worn therapeutic designed to deliver personalized, noninvasive median nerve stimulation targeting autonomic pathways involved in AF. The oversubscribed $30M Series A will support its next phase of clinical development, including the planned NeuroPulse 2 pivotal study.

FOUNDERS: Amos Ziv & Tsahi Holand

INVESTORS: Metis MedTech & Catalyst Health Ventures

ROUND: Series A AMOUNT: $30,000,000

HQ: Los Angeles, California

#VentureCapital #StimCardioMedical #TradedPartner #AmosZiv #TradedVC